| 2025-09-24 | +63.1% | news | MarketWatch | Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it - MarketWatch |
| 2025-09-23 | +61.1% | news | simplywall.st | ClearPoint Neuro Insiders Sold US$543k Of Shares Suggesting Hesitancy - simplywall.st |
| 2024-08-08 | +35.1% | news | Seeking Alpha | ClearPoint Neuro: My Favorite Growth Stock (NASDAQ:CLPT) - Seeking Alpha |
| 2024-08-07 | +34.2% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-10-02 | +30.8% | news | Seeking Alpha | ClearPoint Neuro: AMT-130 Highlights A Bright Future |
| 2025-10-02 | +30.8% | news | Seeking Alpha | ClearPoint Neuro: AMT-130 Highlights A Bright Future (NASDAQ:CLPT) - Seeking Alpha |
| 2026-03-06 | +25.2% | legal | Yahoo Finance | How The ClearPoint Neuro (CLPT) Investment Story Is Shifting After FDA Feedback And Valuation Cut - Yahoo Finance |
| 2026-03-06 | +25.2% | earnings | Stock Titan | Brain navigation firm ClearPoint Neuro sets March 17 earnings call - Stock Titan |
| 2023-11-09 | -24.9% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-12-09 | +24.6% | news | Seeking Alpha | ClearPoint: Fundamentals Continue To Improve |
| 2025-11-03 | -23.5% | news | simplywall.st | Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment? - simplywall.st |
| 2025-11-03 | -23.5% | news | TechStock² | ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive - TechStock² |
| 2024-01-08 | +20.9% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-02-28 | -18.9% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2021-08-10 | -18.0% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-03-12 | +18.0% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-18 | -16.1% | earnings | MarketBeat | ClearPoint Neuro Q4 Earnings Call Highlights |
| 2026-03-18 | -16.1% | news | MT Newswires | Top Premarket Decliners |
| 2026-03-18 | -16.1% | earnings | Moby | ClearPoint Neuro, Inc. Q4 2025 Earnings Call Summary |
| 2026-03-18 | -16.1% | earnings | Seeking Alpha | ClearPoint Neuro plunges as FY26 guidance falls below analysts' estimates |
| 2026-03-18 | -16.1% | earnings | Seeking Alpha | ClearPoint Neuro plunges as FY26 guidance falls below analysts' estimates - Seeking Alpha |
| 2026-03-18 | -16.1% | news | Benzinga | Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga |
| 2025-02-27 | -15.6% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript |
| 2025-10-01 | +14.5% | news | Stock Titan | Revolutionary Robot-Guided Brain Navigation System: ClearPoint Neuro's New Platform for Gene Therapy Delivery - Stock Titan |
| 2024-11-07 | -14.1% | legal | SEC EDGAR | CLPT 8-K: 1.01 and (SEC Filing) |
| 2024-11-07 | -14.1% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-05 | +13.7% | analyst | GuruFocus | ClearPoint Neuro (CLPT) Target Price Lowered but Rating Maintained | CLPT Stock News - GuruFocus |
| 2025-02-26 | -13.5% | earnings | Seeking Alpha | ClearPoint Neuro reports Q4 results |
| 2025-02-26 | -13.5% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-07-22 | +13.4% | earnings | Zacks Investment Research | What date does ClearPoint Neuro's (CLPT) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-03-09 | +12.5% | news | Yahoo Finance | ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last? - Yahoo Finance |
| 2026-03-17 | -11.7% | earnings | Motley Fool | ClearPoint Neuro (CLPT) Earnings Call Transcript |
| 2026-03-17 | -11.7% | earnings | Seeking Alpha | ClearPoint Neuro outlines $52M–$56M 2026 revenue target as company advances growth strategy and integrates IRRAS acquisition |
| 2026-03-17 | -11.7% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript |
| 2026-03-17 | -11.7% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. reports Q4 results |
| 2026-03-17 | -11.7% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-17 | -11.7% | earnings | Quiver Quantitative | ClearPoint Neuro Inc. (CLPT) Stock Falls on Q4 2025 Earnings - Quiver Quantitative |
| 2026-03-17 | -11.7% | earnings | Yahoo Finance | ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2026-03-17 | -11.7% | news | Stock Titan | Brain-surgery device firm ClearPoint expects $52M–$56M in 2026 sales - Stock Titan |
| 2026-03-17 | -11.7% | earnings | Investing.com | Earnings call transcript: ClearPoint Neuro Q4 2025 sees revenue growth, stock up - Investing.com |
| 2025-09-25 | +11.7% | news | Seeking Alpha | ClearPoint Neuro: Selling The Tools For Brain Therapies |
| 2025-09-25 | +11.7% | news | Seeking Alpha | ClearPoint Neuro: Selling The Tools For Brain Therapies (NASDAQ:CLPT) - Seeking Alpha |
| 2023-01-11 | +11.4% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-22 | +11.4% | news | Stock Titan | New brain surgery software opens CT-guided option for hospitals without MRI - Stock Titan |
| 2025-08-12 | +11.0% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. GAAP EPS of -$0.21 misses by $0.01, revenue of $9.2M in-line |
| 2025-08-12 | +11.0% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-10 | +10.8% | news | Stock Titan | ClearPoint Neuro (NASDAQ: CLPT) seeks approval for larger equity incentive plan - Stock Titan |
| 2021-09-16 | +10.6% | news | The Motley Fool | ClearPoint Neuro - CLPT - Stock Price & News - The Motley Fool |
| 2025-08-13 | +10.5% | legal | Seeking Alpha | ClearPoint Neuro outlines global expansion plans and anticipates regulatory milestones while advancing cell and gene therapy initiatives |
| 2025-08-13 | +10.5% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript |
| 2025-05-13 | -9.7% | earnings | Seeking Alpha | ClearPoint Neuro reports Q1 results |
| 2025-05-13 | -9.7% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-06-03 | +9.6% | news | GuruFocus | ClearPoint Neuro (CLPT) Anticipates Boost from AMT-130 Partnersh - GuruFocus |
| 2025-05-14 | -9.6% | news | Seeking Alpha | ClearPoint Neuro targets 15–20 new site activations in 2025 while advancing cell and gene therapy initiatives |
| 2025-05-14 | -9.6% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript |
| 2025-11-12 | -9.3% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. (CLPT) Q3 2025 Earnings Call Transcript |
| 2025-11-12 | -9.3% | news | Seeking Alpha | ClearPoint Neuro: CRO Facility Should Reaccelerate Growth |
| 2025-11-12 | -9.3% | news | Seeking Alpha | ClearPoint Neuro: CRO Facility Should Reaccelerate Growth (NASDAQ:CLPT) - Seeking Alpha |
| 2025-06-11 | -9.2% | executive | Investing.com | ClearPoint Neuro CEO Joseph Burnett sells shares worth $282k - Investing.com |
| 2025-03-25 | -8.6% | news | GuruFocus | ClearPoint Neuro Inc (CLPT) Shares Gap Down to $13.235 on Mar 25 - GuruFocus |
| 2022-08-09 | +8.6% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-10 | +8.3% | earnings | simplywall.st | ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues - simplywall.st |
| 2026-04-20 | -8.2% | news | MT Newswires | ClearPoint Neuro Receives Canada Approval for Neuro Navigation System |
| 2026-04-20 | -8.2% | news | ACCESS Newswire | ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint |
| 2026-04-20 | -8.2% | news | Stock Titan | Canada clears ClearPoint brain navigation system for clinical trial sites - Stock Titan |
| 2026-04-20 | -8.2% | news | Stock Titan | Bigger Capital Group (CLPT) files ownership update showing 7.54% attributed to Michael Bigger - Stock Titan |
| 2026-01-05 | +7.6% | legal | SEC EDGAR | CLPT 8-K: 1.01 and 2.03 (SEC Filing) |
| 2021-06-28 | -7.2% | legal | SEC EDGAR | CLPT 8-K: 8.01 and (SEC Filing) |
| 2021-11-09 | -7.1% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-10 | -6.9% | news | TradingView | CLPT Options Chain — NASDAQ:CLPT - TradingView |
| 2026-04-23 | +6.8% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | ClearPoint (CLPT): Buy, Sell, or Hold? | Q4 2025: Earnings Fall Short - Community Sell Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2023-05-11 | -6.7% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-05-11 | +6.2% | legal | SEC EDGAR | CLPT 8-K: 2.02 and (SEC Filing) |
| 2025-11-06 | -5.9% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. GAAP EPS of -$0.21 misses by $0.01, revenue of $8.86M misses by $0.74M |
| 2025-11-06 | -5.9% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-06 | -5.9% | legal | SEC EDGAR | CLPT 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-11-06 | -5.9% | earnings | Yahoo Finance | ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance |
| 2025-11-06 | -5.9% | M&A | Stock Titan | ClearPoint Neuro (NASDAQ: CLPT) to acquire IRRAS; $0.5B intracranial bleeding market - Stock Titan |
| 2025-11-06 | -5.9% | earnings | simplywall.st | ClearPoint Neuro (CLPT): Assessing Valuation Ahead of Anticipated Quarterly Earnings and Positive Analyst Outlook - simplywall.st |
| 2025-11-06 | -5.9% | earnings | GuruFocus | ClearPoint Neuro (CLPT) Q3 Earnings Miss Estimates - GuruFocus |
| 2026-01-27 | -5.8% | news | Seeking Alpha | ClearPoint Neuro: From Validation To Scale |
| 2026-01-27 | -5.8% | news | Seeking Alpha | ClearPoint Neuro: From Validation To Scale (NASDAQ:CLPT) - Seeking Alpha |
| 2025-02-25 | +5.6% | earnings | Seeking Alpha | ClearPoint Neuro Q4 2024 Earnings Preview |
| 2024-07-27 | -5.3% | news | InvestorPlace | The 3 Best Brain-Computer Interface Stocks to Buy Now - InvestorPlace |
| 2022-09-20 | -4.8% | legal | SEC EDGAR | CLPT 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-13 | -4.8% | news | Stock Titan | MAK Capital (CLPT) reports 1.73M shares, 6.1% stake in ClearPoint - Stock Titan |
| 2025-02-28 | -4.4% | news | Seeking Alpha | ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen |
| 2022-02-15 | +4.4% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-20 | +4.3% | executive | Stock Titan | ClearPoint Neuro (CLPT) CEO exercises options and holds all shares - Stock Titan |
| 2021-11-02 | +4.3% | legal | SEC EDGAR | CLPT 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-19 | -4.1% | earnings | Insider Monkey | ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2025 Earnings Call Transcript - Insider Monkey |
| 2023-08-08 | -3.9% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-04-06 | -3.7% | expansion | Simply Wall St. | Why The ClearPoint Neuro (CLPT) Investment Story Is Shifting On Regulatory And Partnership Risks |
| 2023-03-01 | -3.7% | legal | SEC EDGAR | CLPT 8-K: 2.02 and (SEC Filing) |
| 2025-08-15 | -3.7% | news | Seeking Alpha | ClearPoint Neuro: Biopharma Momentum Continues To Build |
| 2026-03-23 | +3.6% | legal | Simply Wall St. | Why The ClearPoint Neuro (CLPT) Story Is Shifting After New Partner And FDA Updates |
| 2025-10-06 | -3.6% | legal | Investing.com | ClearPoint Neuro expands regulatory approvals to 34 countries - Investing.com |
| 2026-03-11 | +3.5% | news | Stock Traders Daily | How Clearpoint Neuro, Inc. (CLPT) Affects Rotational Strategy Timing - Stock Traders Daily |
| 2026-01-20 | -3.5% | news | Yahoo Finance | While institutions own 40% of ClearPoint Neuro, Inc. (NASDAQ:CLPT), individual investors are its largest shareholders with 52% ownership - Yahoo Finance |
| 2025-08-11 | -3.5% | earnings | Seeking Alpha | ClearPoint Neuro Q2 2025 Earnings Preview |
| 2025-05-12 | -3.3% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. Q1 2025 Earnings Preview |
| 2025-05-12 | -3.3% | legal | SEC EDGAR | CLPT 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-05-12 | -3.3% | news | Stock Titan | ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing - Stock Titan |
| 2025-05-04 | -3.2% | news | Intellectia AI | CLPT Forecast — Price Prediction for 2026. Should I Buy CLPT? - Intellectia AI |
| 2024-05-16 | -3.1% | legal | SEC EDGAR | CLPT 8-K: 5.02, 5.07 (SEC Filing) |
| 2022-09-09 | -3.0% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for ClearPoint Neuro (CLPT) - Zacks Investment Research |
| 2026-01-12 | -3.0% | earnings | Seeking Alpha | ClearPoint Neuro announces preliminary unaudited fourth quarter and full year 2025 revenue |
| 2026-01-12 | -3.0% | legal | SEC EDGAR | CLPT 8-K: 2.02 and (SEC Filing) |
| 2026-01-12 | -3.0% | earnings | Stock Titan | Brain navigation firm lifts quarterly sales 20%, expects up to $60M in 2026 - Stock Titan |
| 2022-06-06 | +2.9% | legal | SEC EDGAR | CLPT 8-K: 8.01 and (SEC Filing) |
| 2023-03-03 | -2.9% | legal | SEC EDGAR | CLPT 8-K: 1.01, 5.02 (SEC Filing) |
| 2025-08-14 | -2.9% | news | Seeking Alpha | ClearPoint Neuro Stock: Biopharma Momentum Continues To Build (NASDAQ:CLPT) - Seeking Alpha |
| 2025-04-29 | -2.8% | news | Seeking Alpha | ClearPoint Neuro: Fundamentals Continue To Strengthen |
| 2025-04-29 | -2.8% | news | Seeking Alpha | ClearPoint Neuro Stock: Fundamentals Continue To Strengthen (NASDAQ:CLPT) - Seeking Alpha |
| 2022-05-11 | +2.7% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-19 | -2.7% | legal | SEC EDGAR | CLPT 8-K: 8.01 and (SEC Filing) |
| 2025-05-23 | +2.4% | legal | SEC EDGAR | CLPT 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-10-16 | +2.3% | news | Moomoo | While ClearPoint Neuro (NASDAQ:CLPT) Shareholders Have Made 248% in 5 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 16% This Week - Moomoo |
| 2025-12-20 | +2.3% | news | simplywall.st | retail investors who own 51% along with institutions invested in ClearPoint Neuro, Inc. (NASDAQ:CLPT) saw increase in their holdings value last week - simplywall.st |
| 2025-04-25 | +2.2% | news | Stock Titan | CLPT Stock Price, News & Analysis - Stock Titan |
| 2025-04-25 | +2.2% | earnings | Stock Titan | ClearPoint Neuro Earnings: Brain Navigation Tech Leader Sets Q1 2025 Financial Review - Stock Titan |
| 2022-08-30 | +2.2% | earnings | TradingView | ClearPoint Neuro Inc. Earnings and Revenue – NASDAQ:CLPT - TradingView |
| 2024-11-10 | -2.2% | news | Seeking Alpha | ClearPoint Neuro: Near-Term Volatility Is No Concern |
| 2024-11-10 | -2.2% | news | Seeking Alpha | ClearPoint Stock: Near-Term Volatility Is No Concern (NASDAQ:CLPT) - Seeking Alpha |
| 2025-06-17 | -2.1% | legal | SEC EDGAR | CLPT 8-K: 1.01 and (SEC Filing) |
| 2026-03-16 | +2.1% | earnings | Seeking Alpha | ClearPoint Neuro, Inc. Q4 2025 Earnings Preview |
| 2026-03-16 | +2.1% | executive | Stock Titan | ClearPoint Neuro (CLPT) CFO nets shares after RSU vesting and tax withholding - Stock Titan |
| 2026-03-16 | +2.1% | news | Stock Titan | ClearPoint Neuro (CLPT) CBO settles RSUs, 15,151 shares for taxes - Stock Titan |
| 2026-04-02 | +2.1% | news | Stock Titan | ClearPoint Neuro (CLPT) director awarded 755 shares as stock compensation - Stock Titan |
| 2026-04-02 | +2.1% | news | Stock Titan | ClearPoint Neuro (CLPT) director receives 1,270-share stock grant as fees - Stock Titan |
| 2026-04-02 | +2.1% | news | Stock Titan | ClearPoint Neuro (CLPT) director granted 442-share stock fee award - Stock Titan |
| 2022-11-08 | -2.0% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-01-31 | +1.9% | news | simplywall.st | ClearPoint Neuro (NASDAQ:CLPT shareholders incur further losses as stock declines 18% this week, taking five-year losses to 47% - simplywall.st |
| 2026-04-21 | -1.9% | news | GlobeNewswire | [Latest] Global Surgical Drill Bits Market Size/Share Worth USD 540 Million by 2035 at a 5.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) |
| 2026-04-21 | -1.9% | earnings | MarketBeat | ClearPoint Neuro (NASDAQ:CLPT) Trading Down 5.3% - Should You Sell? - MarketBeat |
| 2026-04-21 | -1.9% | news | 富途牛牛 | ClearPoint Neuro, Inc. (NASDAQ:CLPT) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable - 富途牛牛 |
| 2024-10-31 | +1.8% | news | Seeking Alpha | ClearPoint Neuro: Investors Enamored With Its Growth Prospects (NASDAQ:CLPT) - Seeking Alpha |
| 2025-06-27 | -1.6% | news | Seeking Alpha | ClearPoint Neuro: Consumables Growth Is Promising |
| 2024-02-15 | -1.4% | news | Seeking Alpha | ClearPoint Neuro Stock: Potential Inflection Point (NASDAQ:CLPT) - Seeking Alpha |
| 2022-02-14 | -1.4% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-11-07 | +1.4% | legal | SEC EDGAR | CLPT 8-K: 1.01 and (SEC Filing) |
| 2022-05-23 | -1.1% | legal | SEC EDGAR | CLPT 8-K: 8.01 and (SEC Filing) |
| 2025-01-27 | +1.1% | legal | Seeking Alpha | ClearPoint Neuro gains FDA clearance for software |
| 2021-07-15 | -1.1% | legal | SEC EDGAR | CLPT 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-26 | -1.0% | news | Stock Titan | Vanguard amendment shows 0% stake in ClearPoint Neuro (CLPT) after realignment - Stock Titan |
| 2023-05-22 | -0.9% | legal | SEC EDGAR | CLPT 8-K: 8.01 and (SEC Filing) |
| 2024-03-01 | +0.9% | legal | SEC EDGAR | CLPT 8-K: 1.01 and (SEC Filing) |
| 2024-05-07 | +0.7% | legal | SEC EDGAR | CLPT 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-20 | -0.7% | legal | SEC EDGAR | CLPT 8-K: 1.01, 2.01, 3.02, 7.01 (SEC Filing) |
| 2025-11-20 | -0.7% | M&A | Stock Titan | ClearPoint (Nasdaq: CLPT) closes IRRAS deal, adding IRRAflow and 50+ customers - Stock Titan |
| 2025-10-23 | +0.4% | legal | DirectorsTalk Interviews | ClearPoint Neuro Inc. (CLPT) Stock Analysis: Exploring a 19% Potential Upside in the Innovative Medical Devices Sector - DirectorsTalk Interviews |
| 2022-03-01 | -0.4% | legal | SEC EDGAR | CLPT 8-K: 2.02 and (SEC Filing) |
| 2026-04-03 | -0.4% | news | Cổng thông tin điện tử tỉnh Tây Ninh | CLPT Stock Analysis: ClearPoint Neuro Inc. medtech gains 2.52 percent at 9.37 - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-22 | -0.3% | legal | ACCESS Newswire | ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint |
| 2026-04-22 | -0.3% | legal | Stock Titan | ClearPoint's brain surgery drill gets FDA clearance, first clinical use - Stock Titan |
| 2026-04-22 | -0.3% | analyst | The Globe and Mail | Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail |
| 2023-08-01 | -0.1% | legal | SEC EDGAR | CLPT 8-K: 1.01 and (SEC Filing) |
| 2023-12-22 | -0.0% | analyst | TradingView | CLPT Forecast — Price Target — Prediction for 2027 - TradingView |